Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.

JR, Teerlink; R, Diaz; GM, Felker; JJV, McMurray; M, Metra; SD, Solomon; KF, Adams; I, Anand; A, Arias-Mendoza; T, Biering-Sørensen; M, Böhm; D, Bonderman; JGF, Cleland; R, Corbalan; MG, Crespo-Leiro; U, Dahlström; LE, Echeverria; JC, Fang; G, Filippatos; C, Fonseca; E, Goncalvesova; AR, Goudev; JG, Howlett; DE, Lanfear; J, Li; M, Lund; P, Macdonald; V, Mareev; SI, Momomura; E, O'Meara; A, Parkhomenko; P, Ponikowski; FJA, Ramires; P, Serpytis; K, Sliwa; J, Spinar; TM, Suter; J, Tomcsanyi; H, Vandekerckhove; D, Vinereanu; AA, Voors; MB, Yilmaz; F, Zannad; L, Sharpsten; JC, Legg; C, Varin; N, Honarpour; SA, Abbasi; FI, Malik; CE, Kurtz

doi:10.1056/nejmoa2025797

Public

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.

Shared by NobleBlocks on Nov 13, 2020 • 12:00 AM UTC

Authors:

Teerlink JR

Diaz R

Felker GM

Abstract

Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown.Methods We randomly assigned 8256 patients (inpatients and outpatients) wi...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!